Halozyme Therapeutics, Inc. (HALO) Stock Price
HALOStock
$105.35+44.69%52W
Market Cap$11.96B
P/E36.06x
PEG Ratio1.21
Div yield—
Beta0.90
HALO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)37.80%
Price vs S&P 500 (4W)26.51%
PEG Ratio1.21
VGM Score63.00
P/E Ratio (Annual)36.06x
HALO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.82 | $2.28 | +25.53%(+$0.46) | |
| Q1 2026 | $1.52 | $1.60 | +5.26%(+$0.08) | |
| Q4 2025 | $2.20 | -$0.24 | -110.92%(-$2.44) | |
| Q3 2025 | $1.63 | $1.72 | +5.51%(+$0.09) | |
| Q2 2025 | $1.27 | $1.54 | +21.45%(+$0.27) |
HALO Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.80
3.75
3.75
3.88
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| TECHBio-Techne Corp. | D | C | B | $72.35 |
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics develops oncology therapies that target human enzymes to alter tumor progression. The company advances its pipeline through both internal development and partnerships with biopharmaceutical companies to commercialize its proprietary technology. Operations are primarily US-based with minimal international assets.